RT Journal Article
SR Electronic
T1 Gender disparities in international COVID-19 clinical trial leadership
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.02.20166751
DO 10.1101/2020.08.02.20166751
A1 Cevik, Muge
A1 Haque, Syed Arefinul
A1 Manne-Goehler, Jennifer
A1 Kuppalli, Krutika
A1 Sax, Paul E.
A1 Majumder, Maimuna S.
A1 Orkin, Chloe
YR 2020
UL http://medrxiv.org/content/early/2020/08/05/2020.08.02.20166751.abstract
AB The COVID-19 pandemic offers considerable possibilities for research and leadership that might equalize opportunity in a new field; however, our study finds instead that more than two-thirds of investigators leading COVID-19-related clinical studies are predicted to be men. These gender disparities in trial leadership during the pandemic suggest that the structural reproduction of inequalities in research has taken place once again in this new academic field. This indicates that policies are needed to facilitate the identification and implementation of strategies to correct gender bias. The active participation of women, trans and gender-nonconforming individuals are needed in research to drive scientific discovery and innovation as well as to better address health disparities.Competing Interest StatementCompeting interests declared in the manuscriptFunding StatementNo funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe repository of the datasets used to collect and analyse the data available at https://osf.io/k2r57/.